Poolbeg Pharma (AIM: POLB), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces the publication of a peer-reviewed paper from the POLB 001 LPS human challenge trial in Frontiers in Immunology.
Professor Cathy Tralau-Stewart, Executive Director of the Milner Therapeutics Institute, has continued her thought leadership work with an article in Drug Discovery World.
Scancell Holdings plc, the developer of active immunotherapies to treat cancer, announces the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for a registrational Phase 3 trial of its iSCIB1+ Immunobody® in advanced melanoma, with progression free survival as the agreed surrogate endpoint.
As 2026 shapes up to an unpredictable year, our policy experts have provided more grounding for what the life sciences sector should expect over the next 12 months. This is the second and final part of our 2026 outlook series.
Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search assignment for TreeFrog Therapeutics and is pleased to announce the placement of Mark Rothera as Chief Executive Officer (CEO).
Stablepharma will apply its proprietary stabilisation technology, initially focused on vaccines, to non-vaccine sterile injectables that currently require cold-chain storage. Stablepharma will be eligible to receive future milestone and royalty revenue from AFT upon commercialisation.
UK biotech has demonstrated resilience in a challenging 2025 and enters 2026 with renewed confidence and broadening investor appetite, the BioIndustry Association’s (BIA) report UK biotech financing 2025 has found.
Our UK biotech financing 2025 report is out today, including data and commentary on how the biotech investment landscape fared last year. 2025 was a brutal year for the sector, but an upswing in deal numbers going into 2026 and recent capital injections give good reason to be optimistic.
In 2025, the UK biotech sector continued to operate in a challenging financing environment, securing £1.9 billion in equity financing. Of this total, £1.8 billion was raised through venture capital, representing a 13.2% decrease year on year.
The Cell and Gene Therapy Catapult (CGT Catapult) has published new insights into the UK’s CGT clinical trials in its 2025 Advanced Therapy Medicinal Product (ATMP) Clinical Trials Database.
Infinitopes announced its second close of its seed financing round, securing an additional $15.4 million and bringing the total raised to $35.1 million.
With a number of unprecedented leaks, speculation and media briefings indicating potential wide ranging and significant tax rises, in the end the 2025 Autumn Budget seemed to be one of restraint and headline rates remained untouched.
NCIMB, the Aberdeen-based microbiology company is delighted to welcome Martin Gouldstone as chairman of the board. Martin brings a wealth of commercial and leadership expertise from drug discovery and contract research.
The BIA and ABPI have jointly responded to Department for Business and Trade consultation on the British Industrial Competitiveness Scheme: consultation on scheme eligibility and approach.
ELRIG announced the keynote speakers for Cell and Gene Therapy 2026 - Drs Stephen Ward (Cell and Gene Therapy Catapult) and Annarita Miccio (Imagine Institute).
